Detalhe da pesquisa
1.
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.
N Engl J Med
; 384(16): 1503-1516, 2021 04 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-33631066
2.
Racial/ethnic disparities on inflammation and response to methylprednisolone in severe COVID-19 pneumonia.
BMC Infect Dis
; 22(1): 254, 2022 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35287602
3.
Methylprednisolone, venous thromboembolism, and association with heparin to 30 days in hospital survival in severe Covid-19 pneumonia.
BMC Pulm Med
; 22(1): 6, 2022 Jan 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34986821
4.
Hydroxychloroquine, azithromycin and methylprednisolone and in hospital survival in severe COVID-19 pneumonia.
Front Pharmacol
; 13: 935370, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36238570
5.
Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA).
EClinicalMedicine
; 47: 101409, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35475258
6.
Hemodynamic Profiles of Shock in Patients With COVID-19.
Am J Cardiol
; 153: 135-139, 2021 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34167784
7.
Methylprednisolone and 60 Days in Hospital Survival in Coronavirus Disease 2019 Pneumonia.
Crit Care Explor
; 3(7): e0493, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34291223
8.
Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.
PLoS One
; 15(8): e0237693, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32790733
9.
Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study.
Lancet Rheumatol
; 2(10): e603-e612, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32838323